Kidney stones are more than just painful - they can cause serious damage to the kidneys and, in severe cases, lead to kidney failure. One rare but serious condition that leads to frequent and severe kidney stones is primary hyperoxaluria, where the body produces too much oxalate, a natural chemical that can form sharp crystals when combined with calcium. Genetic data such as the data 46forALL plans to collect can enable researchers to pinpoint specific genes with mutations responsible for inherited forms of kidney stones. This has significantly advanced understanding of how gene mutations contribute to kidney stones. The genes AGXT, GRHPR, and HOGA1, for example, are responsible for breaking down oxalate (a chemical produced by the liver). Mutations in these genes cause too much oxalate to build up, leading to the formation of calcium oxalate stones in the kidney. Understanding the impact of the mutated genes and excessive oxalate prompted scientists to develop a drug called Lumasiran which blocks the liver’s production of oxalate, preventing the buildup of oxalate and formation of stones. Lumasiran is able to limit the production of oxalate by delivering specific RNAi (RNA interference) to the liver to bind with the mRNA (messenger RNA) of the mutated gene and silence the glycolate oxidase enzyme which is responsible for the output of oxalate. Due to specifically targeting the metabolic pathway that leads to oxalate production, Lumasiran does not otherwise interfere with the metabolic process. This is a powerful example of how studying genetic data can lead to life-changing therapies—and your participation in genetic research could help unlock the next breakthrough.